Beam Therapeutics is a biotechnology company focused on developing precision genetic medicines using its proprietary base editing technology. The company's platform allows for precise and efficient editing of single base pairs in DNA and RNA, which has the potential to treat a wide range of genetic diseases. Beam Therapeutics' lead product candidate, BEAM-101, is a potential treatment for sickle cell disease and beta-thalassemia. The company was founded in 2017 and is headquartered in Cambridge, Massachusetts.